How to Open a Ketamine Clinic: The Complete Guide

Stephanie Karzon Abrams, Clinical neuropharmacologist | Clinical Director Mystic Health | Founder, Beyond Consulting | Research Director, Microdosing Collective 501c3

There is a version of this that works, a version that doesn't, and an enormous amount of noise between them where consultants who have never run a clinic or worked in one, courses that cover pharmacology and clinical training, but not operations, financial strategy, or team dynamics, which  frameworks built for a different era of the field.

This guide was written by people who have built ketamine practices, sat in the rooms during infusions, and helped clinics navigate everything from their first DEA registration to the question of what music to play. It is as complete and honest as we can make it, which means it will occasionally tell you things you'd rather not hear.

If you are a clinician considering adding ketamine-assisted therapy to your practice, a founder exploring this as a business, or someone somewhere in between — this is where to start.

Table of Contents

1. Is a Ketamine Clinic Right for Your Practice?

2. Understanding the Legal Landscape

3. Entity Structure and Business Formation

4. DEA Registration and Controlled Substance Compliance

5. Clinical Protocols and Patient Selection

6. Physical Space and Equipment

7. Staffing Your Practice

8. Financial Modeling: What It Actually Costs

9. Patient Experience and Integration

10. Marketing, Referrals, and Growth

11. What COMP360 Means for Your Timeline

12. How to Know If You're Ready
    

Is a Ketamine Clinic Right for Your Practice?

Treatment-resistant depression affects approximately 30% of the estimated 280 million people worldwide living with depression. Anxiety disorders, PTSD, OCD, chronic pain, and suicidal ideation are all being studied and treated with ketamine protocols. The demand is real. The evidence base is strong. The regulatory pathway, relative to every other psychedelic compound, is as clear as it's ever been.

What far too many people underestimate is what it takes to run this practice well.

Your success will not be tied to revenue add-ons or attracting spa-curious clientele with wellness treatments. Your success  is in clinical operations within medical, ethical, and regulatory dimensions, and it requires genuine investment — financially, operationally, intellectually.

Ask yourself honestly: do you have prescribing authority, or a relationship with someone who does? Do you have a real interest in the therapeutic dimensions of this work, not just the pharmacological ones? Are you prepared to invest in training, physical space, compliance, and a patient experience that goes beyond the infusion itself?

The practices that survive long-term started from a place of clinical mission and built the business around it.

If the answers are yes, keep reading.

Understanding the Legal Landscape

Ketamine is a Schedule III controlled substance under the Controlled Substances Act . It is the same schedule as anabolic steroids and certain combination opioid products. This is significantly more permissive than Schedule I (psilocybin, MDMA, LSD) or Schedule II (fentanyl, oxycodone), which is why ketamine is the only psychedelic (dissociative) compound currently viable as a standalone clinical offering in the US without a research exemption.

It use for depression, anxiety, PTSD, and chronic pain is off-label. The only FDA-approved indications are anesthesia and, for esketamine specifically, treatment-resistant depression and major depressive disorder with acute suicidality (Spravato, J&J). Off-label prescribing is legal and widely practiced in American medicine; it means the prescriber takes on clinical responsibility for the decision.

A few things vary by state and are worth confirming with a healthcare attorney in your jurisdiction. For example, a nurse practitioner cannot prescribe or administer ketamine in the state of Louisiana; only an MD can prescribe and administer, and a CRNA can administer. In Florida, RNs can’t push ketamine either. 

Scope of practice is the first question. Who can prescribe ketamine depends on your state — in most, MDs, DOs, and nurse practitioners with prescribing authority can do so; some states have NP practice restrictions that affect how a ketamine clinic can be structured. Telemedicine rules are the second. The Ryan Haight Act historically required an in-person evaluation before prescribing controlled substances via telemedicine; post-COVID flexibilities have allowed virtual prescribing in some contexts, but those rules are still in flux. Corporate practice of medicine is the third. Many states prohibit non-physician-owned corporations from employing physicians directly, which affects your business structure significantly. And malpractice coverage — not all carriers cover ketamine-assisted therapy. Confirm yours before you administer a single infusion.

The key here is knowing about your team, its specialties, and your scope of practice and operations, so that when you chat with malpractice carriers or even the state medical board you can point them to the realities of your practice and get the right answers. Some clinics prepare a ghost submission (a preliminary or test-submission) for malpractice carriers, which will allow underwriters to tell you what will be covered, what will not, and what might cost more to cover. Then you can make decisions on how to build and run your practice based on this feedback. 

Entity Structure and Business Formation

How you structure your ketamine practice legally has significant implications for liability, taxation, and how you can bring in partners or investors. The right structure depends on your state, your professional background, and whether you are a clinician-founder or a non-clinician entrepreneur.

The Professional Limited Liability Company (PLLC) is the most common structure for clinician-owned practices. It provides liability protection while allowing clinical professionals to own and operate the business, and is required in many states for any entity providing medical services directly.

The Management Services Organization model is the most viable structure for non-clinician founders, or for practices that want to separate business operations from clinical services. The MSO, owned by the entrepreneur, provides management and administrative services to a separately owned clinical entity, typically owned by a licensed physician or NP. The two entities contract with each other. This is the structure behind most venture-backed healthcare companies, and it exists for a reason.

Whatever structure you choose, have a healthcare attorney review it before you file anything. The regulatory exposure from getting this wrong is not theoretical.

DEA Registration and Controlled Substance Compliance

Any practice prescribing or administering ketamine must have a DEA Controlled Substance Registration. Apply at dea.gov. You will need a valid state medical or prescribing license, a physical practice address, proof of your state-level authority to handle controlled substances, and the registration fee ($888). Processing typically takes four to six weeks, sometimes longer.

Most states have their own controlled substance registration requirements in addition to the federal DEA registration. In California, for example, practitioners must register with CURES and check it before prescribing. Know your state's requirements before you get your federal registration and assume you're done.

Ketamine must be stored in a securely locked, substantially constructed cabinet. You must maintain accurate records of all ketamine received, administered, and disposed of, and reconcile inventory regularly. Theft or significant loss must be reported to the DEA immediately on Form 106. Unused or expired ketamine cannot simply be discarded — it must go through a DEA-registered reverse distributor or to a DEA-authorized collection site.

DEA investigators can and do conduct unannounced inspections. Your recordkeeping and storage need to be in order at all times, not just when you're expecting someone.

Clinical Protocols and Patient Selection

This is where the clinical quality of your practice lives or dies.

The pharmacology is the same everywhere, but the protocols are not. A practice that treats patient selection as a formality and preparation as optional is not practicing ketamine-assisted therapy in any meaningful sense. It is administering a drug and hoping for the best. Ketamine can produce rapid anti-depressant effects, but its prolonged effects are tied to the addition of psychotherapeutic support, and it’s full potential as a psychedelic therapy is also tied to things like meaning making, learning and plasticity, exploration of identity, and spirituality. Things that create more depth for the patient. Things that take it from pharmacotherapy to transformation therapy. 

Every patient should undergo a comprehensive intake process before being considered for treatment. At minimum: a full psychiatric history, a medical history focused on cardiovascular health, blood pressure, and any history of psychosis or mania, a substance use history, and current medications — with particular attention to drugs that interact with ketamine, including benzodiazepines, MAOIs, and certain stimulants.

Absolute contraindications include uncontrolled hypertension, active psychosis, active mania without mood stabilization, and pregnancy (though there are some cases of treatment in the third trimester as a prophylactic treatment for postpartum depression). Relative contraindications requiring careful clinical judgment include substance use disorder particularly involving dissociatives, history of dissociative episodes outside of a therapeutic context, significant trauma history without any prior therapeutic relationship, and a highly avoidant or defended psychological presentation.

The patients who respond best tend to be genuinely treatment-resistant — having failed at least two adequate antidepressant trials — psychologically curious rather than highly defended, and willing to move with the experience rather than resist it. That last quality is harder to assess on paper and easier to evaluate in conversation. Build your intake process to find it.

On routes of administration: IV, IM, sublingual, and nasal spray (Spravato) each have different clinical profiles, monitoring requirements, and appropriate use cases. IV offers the most precise dosing and the most robust evidence base; it requires the most infrastructure. Sublingual has the lowest barrier but the most variable bioavailability. IM produces a faster, more intense experience. Match the modality to your clinical goals, your patient population, and your setting. There is no universally superior option.

Standard IV antidepressant dosing is 0.5 mg/kg to 1 mg/kg over 40-60 minutes, typically as a series of six infusions over three to six weeks. These are starting points, not fixed protocols. Clinical judgment, patient response, and ongoing monitoring should shape your approach throughout. Intramuscular injection follows the same dosing range. Doses can reach 1.5 mg/kg, although this is the higher range and begins to move towards anesthesia. The goal is for your patient to recall their experience, therefore sub-anesthetic doses are key. IM injections can be split into ⅓ - ⅔ or 60-40, or 50/50. This is where your understanding of ketamine, of the patient and their experience, and of the arc of a ketamine session are necessary. This is the art of ketamine therapy. And that same “art” can be practiced with IV; with various rates of infusions and programmed boluses. 

Physical Space and Equipment

The environment of a ketamine session is not incidental to the outcome. The research on this is consistent.

A recovery-bay aesthetic with fluorescent lighting and beeping monitors is not the same clinical context as a warm, intentionally designed room with appropriate lighting and music. The latter produces better outcomes. This is not aesthetic preference — it is clinical evidence.

Each treatment room needs a reclining chair or comfortable treatment surface, room for monitoring equipment, adequate space for a clinician to be present without crowding the patient, and acoustic separation sufficient for patients to have private experiences without disturbing or being disturbed by others. Lighting should be dimmable and warm-toned, with the ability to darken the room significantly for the acute session phase.

Music is the most underinvested element of ketamine practice in the US, and it matters more than most clinicians initially believe. A 2018 study by Kaelen et al. found that the nature of the music experience during a psychedelic session was more predictive of outcomes one week later than general drug intensity. Invest in creating or finding a curated playlist or use one of the established therapeutic music platforms. Do not leave music to chance or to the patient's Spotify on shuffle. Features such as “crossfade” or “mix” on Spotify now allow you to blend the songs in a playlist seamlessly, avoiding stops and lulls between songs. The Soundcloud streaming platform also has many mixed playlists as well. It might take some digging to find what you resonate with. A patient’s preference can be taken into account, and in some instances they've curated a great playlist for themselves. The choice of music can also be used to create tension or to calm and ground. Not every playlist needs to offer comfort. Playlists can also build and rise in tension to help a patient access certain emotions or memories. Working closely with the patient to understand how music can shape their journey is an important part of this therapy. 

For IV administration: an IV pump or gravity drip setup, standard IV supplies, monitoring equipment including blood pressure cuff and pulse oximeter, emergency medications including flumazenil, and a crash cart if your patient population warrants it.

IM requires less equipment as it is a simple injection (two or three if total dose is split). 

Patients need time and space to return to baseline after a session before leaving. This can be the treatment room itself or a separate recovery area, but it should be calm, supervised, and unhurried.

Staffing Your Practice

The prescriber is required. They must have a valid DEA registration and state prescribing authority for controlled substances, and they must be involved in intake, the clinical decision to treat, and the management of adverse events. In a PLLC, this is typically the clinician-founder. In an MSO model, this is the clinician-owner of the clinical entity.

The session monitor is someone trained and present during every infusion. Depending on your state and modality, this may need to be an MD/NP, CRNA/RN or may allow for a trained medical assistant. Their job is to monitor vitals, be present for the patient during the session, manage any acute adverse events, and support recovery. Supervision models vary. Your practice can decide how hands-on you'd like to be. Patients can also have requests for more privacy and frequent check-ins, or full supervision the entirety of their session. Some models also have therapists guiding a lower-dose session. This is usually a decision between clinician and therapist. 

The integration therapist or coach is not universally required, but consistently associated with better outcomes. If your model does not include in-house integration, you should have a referral network of therapists who understand non-ordinary states and can provide follow-up support. Do not build a practice without this component and call it KAP or KAT. It isn't.

Administrative and patient coordination staffing is almost always needed earlier than founders expect. Intake coordination, scheduling, follow-up, documentation, and billing all require dedicated capacity. This is not the prescriber's job.

The clinic doing six patients a week from one room is a different operation from the one doing thirty patients across three rooms. Build your staffing model to grow, not just to open.

Financial Modeling: What It Actually Costs

Nobody talks about this clearly enough! 

Start-up costs vary widely depending on whether you are converting an existing exam room in an established practice or building a standalone ketamine clinic from scratch in a competitive market. Here are realistic ranges:

Legal and entity formation runs $3,000 to $15,000. DEA registration is $888. Build-out and design ranges from $15,000 to $150,000 or more depending on your market and your vision for the space. Equipment , IV, monitoring, runs $5,000 to $30,000. An initial ketamine supply costs $500 to $3,000. EMR and practice management software is $2,000 to $10,000 per year. Malpractice insurance is $3,000 to $12,000 per year. Staff training runs $2,000 to $15,000. Marketing and website, $3,000 to $20,000. Three months of working capital, which you will need, is $30,000 to $100,000.

Total: somewhere between $65,000 and $350,000, depending on where you start. We always say to be ready to spend 500K. 

On the revenue side: a single-room practice doing ten IV infusions per week at $400 to $600 per infusion generates $4,000 to $6,000 in weekly gross revenue. A six-session series priced at $2,400 to $3,600 is the common packaging model. At two rooms doing twenty infusions per week, gross revenue is $8,000 to $12,000 per week. At 80% overhead: staffing, supplies, rent, administrative. Net margin is approximately $80,000 to $120,000 per year from two rooms running at capacity.

What people routinely underestimate: the time from first patient inquiry to first infusion, which with a proper intake process is typically two to four weeks. The cost of patient acquisition, which in a cash-pay model requires active referral development. The administrative burden, which almost always requires dedicated staffing sooner than founders expect. And the cost of integration, which if not built into the model will be either absorbed as unprofitable service or excluded to the detriment of patient outcomes.

Don’t forget to account for the model you’ll create to compensate your clinicians. It can look however you want it to look. If you're building from scratch with no patient-base, start lean, and bring staff on that can wear many hats. Staff who are willing to grow with you and can be flexible in compensation structures. This might look like part-time hires who can give you 1-2/week, while having another job that pays their bills. 

Patient Experience and Integration

The clinical literature on ketamine has largely been a literature about pharmacology. What it doesn't capture well is the human dimension of the work, and that is where most of the variance in patient outcomes lives.

The antidepressant effect is real and rapid. It is also, without supporting structure, often temporary. The window of neuroplasticity that ketamine opens — the period after treatment during which the brain is more receptive to forming new patterns — is the most therapeutically valuable real estate in the entire model. What goes into that window matters.

Integration is not an optional premium feature in KAP. It is the mechanism by which pharmacological effects become lasting behavioral and psychological change. Practices that invest in integration consistently outperform those that don't: on patient outcomes, on retention, on word-of-mouth referrals, and on the business itself.

At minimum, integration includes a structured follow-up conversation after each session, a framework for making meaning of the experience, and some scaffolding for the behavioral changes the patient is working toward. Whether this happens within your practice through a licensed therapist, or through a referral relationship you've built with integration-literate providers in your community, it has to happen.

Music, covered above, is part of this. Preparation before the session is part of this. The totality of the patient's experience, from first inquiry through the final follow-up,  is part of this. The practices that understand this are the ones patients talk about. They are also the hardest to compete with.

Marketing, Referrals, and Growth

Ketamine therapy is a cash-pay service in a category that still carries stigma. Both facts shape how you market it.

On the ethical side: the FDA and FTC have both issued guidance on healthcare marketing, and ketamine has attracted particular regulatory attention given the growth of telehealth prescribing.
-Do not make unsubstantiated efficacy claims. -Do not use patient testimonials in ways that violate HIPAA.
-Do not imply that ketamine is FDA-approved for depression. Only esketamine is.
-Describe it accurately as an off-label treatment with a growing evidence base.
-Get LegitScript certified if you plan to market online (ads), and start the process early as it can be lengthy! 

Referral networks are your primary growth lever. Most ketamine patients arrive through referrals — from psychiatrists whose patients are treatment-resistant, from therapists whose clients have exhausted other options, from PCPs who want a trusted destination. Building these relationships is slower than paid advertising and more durable. A psychiatrist who trusts you and sends five patients a month is worth more than a Facebook campaign, and they tend to keep sending.

Start building before you open your doors. Engage the community and engage a few providers. If you have a waitlist before opening, that will help you anticipate staffing needs and form an early schedule. 

Your digital presence needs to clearly explain what ketamine therapy is, who it is for, what to expect, what it costs, and how to get started. It should also answer the questions people search before picking up the phone. Content like this guide matters for patient acquisition as well as for professional credibility, and the two are not as separate as they might appear.

Word of mouth compounds and patients who have meaningful experiences tell people. Build the practice that deserves to be talked about.

Google reviews are important! Not just for SEO and Google authority but for trust building. It is a competitive market. The more positive reviews, speaking to specific elements and unique characteristics about your practice the better. Photos of your space are great so people can connect with the environment and start envisioning their journey. Patient testimonials are also important. This remains a private experience that some people aren’t willing to share publicly about, but there are always a select few who are willing, so it’s always worth asking. 

What COMP360 Psilocybin or other FDA approved Psychedelic Medicines mean for Your Timeline

COMP360, Compass Pathways' synthetic psilocybin, is on a regulatory pathway that could result in FDA approval within the next twelve to twenty-four months, with a rolling NDA submission targeted for late 2026. The FDA has directed Compass to look to the Spravato REMS as a reference framework, a detail Compass disclosed in its own communications, which means the infrastructure requirements for COMP360-certified clinics will look meaningfully similar to what a well-run ketamine practice already has in place.

The clinics positioned to add COMP360 most quickly, with the least friction and the shortest learning curve, are those that have already built IV or IM monitoring infrastructure, trained staff comfortable with non-ordinary states, integration protocols, a regulatory-compliant operations model, and a patient population that has been educated about the therapeutic use of psychedelic compounds. A COMP360 treatment session will likely be 4-6 hours, so this will take operational strategy. 

Ketamine practice, in this sense, is positioning for what comes next. The investment you make now in clinical quality, operational infrastructure, and patient experience is not only a ketamine investment. It's a foundation.

If you want to understand your specific COMP360 readiness, our COMP360 Psilocybin Readiness hub covers the regulatory landscape and what clinics need to have in place.

Other medicines on the horizon are a 5-Meo-DMT nasal spray, which will be fast and short acting and comparable to Spravato operationally, as those sessions also involve a nasal spray and 120 min in clinic. DT120 ODT is a proprietary, pharmaceutically optimized oral formulation of lysergide (LSD) D-tartrate. It will be a much longer session; on average 6 hours. The REMS requirements relative to a patient’s required stay in the clinic and beyond are still unknown. 

How to Know If You're Ready

There is a useful difference between feeling ready and being ready. Most founders feel ready before they are. Some are more ready than they realize! 

The six domains that determine readiness — clinical and medical infrastructure, physical space and equipment, legal and compliance, financial modeling, patient experience, and marketing and referral capacity — are not equally weighted. A practice with strong clinical infrastructure and a weak marketing plan can still open and grow. A practice with strong marketing and weak clinical infrastructure will run into serious problems, likely at the moment it can least afford them.

The most honest way to evaluate your readiness is systematically. Our Ketamine Therapy Readiness Assessment is a scored evaluation across all six domains that tells you where you are strong, where you have gaps, and what to address before you open. It takes about fifteen minutes. Our team follows up within forty-eight hours.

If you are past the assessment stage and ready to build, our clinic consulting services are designed for exactly this point from entity structure and DEA registration through clinical protocol development, physical space design, staffing, and launch.

The field needs more practices built well, and the patients who will benefit from this work need providers who took the time to get it right. They will feel and know the difference! 

Get in touch HERE

Stephanie Karzon Abrams, Clinical neuropharmacology | Founder, Beyond Consulting